1-3 of 3
Richard Leuchter
Close
Sort by
Journal Articles

The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.

Dror Shalitin, PhD, Michael Share, BA, Richard A. Campbell, BS, Jeffrey Steinberg, BS, Eric Sanchez, BA, Joseph Wang, Richard Leuchter, Mingjie Li, Cathy S. Wang, BS, Haiming Chen, MD, PhD, James R. Berenson, MD
Journal: Blood
Blood (2007) 110 (11): 4800.
https://doi.org/10.1182/blood.V110.11.4800.4800
Published: 2007
Journal Articles

The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth In Vivo and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide.

Richard A. Campbell, BS, Eric Sanchez, BA, Jeffrey Steinberg, BS, Michael Share, BA, Joseph Wang, Mingjie Li, Richard Leuchter, Haiming Chen, MD, PhD, Dror Shalitin, PhD, Shen Pang, PhD, Jonathan Said, MD, James R. Berenson, MD
Journal: Blood
Blood (2007) 110 (11): 4801.
https://doi.org/10.1182/blood.V110.11.4801.4801
Published: 2007
Journal Articles

An Anti-VEGF Antibody, in Combination with Bortezomib, Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma.

Richard A. Campbell, BS, Eric Sanchez, BA, Jeffrey Steinberg, BS, Michael Share, BA, Joseph Wang, Mingjie Li, Richard Leuchter, Haiming Chen, MD, PhD, Dror Shalitin, PhD, Shen Pang, PhD, Jonathan Said, MD, Gregory D. Plowman, PhD, James R. Berenson, MD
Journal: Blood
Blood (2007) 110 (11): 4802.
https://doi.org/10.1182/blood.V110.11.4802.4802
Published: 2007